Mitumomab

Mitumomab (BEC-2) is a mouse anti-BEC-2 monoclonal antibody investigated for the treatment of small cell lung carcinoma in combination with BCG vaccination. Mitumomab attacks tumour cells, while the vaccine is thought to activate the immune system. It was developed by ImClone and Merck.[1]

Mitumomab
Monoclonal antibody
TypeWhole antibody
SourceMouse
TargetGD3 ganglioside
Clinical data
ATC code
  • none
Identifiers
CAS Number
IUPHAR/BPS
ChemSpider
  • none
UNII
KEGG
 NY (what is this?)  (verify)

The first phase III clinical trial began in 1998.[2][3] In 2005 and again in 2008, results were published showing no benefit to patients receiving mitumomab and BCG.[4][5]

See also

References
  1. "Mitumomab - AdisInsight". Adisinsight.springer.com. 2005-06-13. Retrieved 2017-01-06.
  2. Clinical trial number NCT00037713 for "Survival in a Randomized Phase III Trial in Patients With Limited Disease (LD) Small Cell Lung Cancer Vaccinated With Adjuvant BEC2 and BCG" at ClinicalTrials.gov
  3. Clinical trial number NCT00006352 for "Monoclonal Antibody Therapy Plus BCG in Treating Patients With Limited-Stage Small Cell Lung Cancer" at ClinicalTrials.gov
  4. Bottomley A, Debruyne C, Felip E, Millward M, Thiberville L, D'Addario G, et al. (October 2008). "Symptom and quality of life results of an international randomised phase III study of adjuvant vaccination with Bec2/BCG in responding patients with limited disease small-cell lung cancer". European Journal of Cancer. 44 (15): 2178–84. doi:10.1016/j.ejca.2008.06.036. PMID 18676140.
  5. Giaccone G, Debruyne C, Felip E, Chapman PB, Grant SC, Millward M, et al. (October 2005). "Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study)". Journal of Clinical Oncology. 23 (28): 6854–64. doi:10.1200/JCO.2005.17.186. PMID 16192577.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.